- Home
- AUTL vs TRTX Comparison
AUTL vs TRTX Comparison
Compare AUTL & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- TRTX
- Stock Information
- Founded
- AUTL 2014
- TRTX 2014
- Country
- AUTL United Kingdom
- TRTX United States
- Employees
- AUTL N/A
- TRTX N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- TRTX Real Estate Investment Trusts
- Sector
- AUTL Health Care
- TRTX Real Estate
- Exchange
- AUTL Nasdaq
- TRTX Nasdaq
- Market Cap
- AUTL 590.8M
- TRTX 695.8M
- IPO Year
- AUTL 2018
- TRTX 2017
- Fundamental
- Price
- AUTL $1.44
- TRTX $8.16
- Analyst Decision
- AUTL Strong Buy
- TRTX Strong Buy
- Analyst Count
- AUTL 5
- TRTX 5
- Target Price
- AUTL $9.32
- TRTX $9.40
- AVG Volume (30 Days)
- AUTL 1.3M
- TRTX 812.7K
- Earning Date
- AUTL 05-13-2025
- TRTX 04-29-2025
- Dividend Yield
- AUTL N/A
- TRTX 11.77%
- EPS Growth
- AUTL N/A
- TRTX N/A
- EPS
- AUTL N/A
- TRTX 0.75
- Revenue
- AUTL $10,120,000.00
- TRTX $148,968,000.00
- Revenue This Year
- AUTL $277.74
- TRTX N/A
- Revenue Next Year
- AUTL $221.89
- TRTX N/A
- P/E Ratio
- AUTL N/A
- TRTX $10.91
- Revenue Growth
- AUTL 496.00
- TRTX N/A
- 52 Week Low
- AUTL $1.40
- TRTX $6.99
- 52 Week High
- AUTL $5.84
- TRTX $9.66
- Technical
- Relative Strength Index (RSI)
- AUTL 32.97
- TRTX 38.15
- Support Level
- AUTL $1.58
- TRTX $7.97
- Resistance Level
- AUTL $1.70
- TRTX $8.62
- Average True Range (ATR)
- AUTL 0.13
- TRTX 0.15
- MACD
- AUTL -0.02
- TRTX -0.04
- Stochastic Oscillator
- AUTL 3.03
- TRTX 28.57
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About TRTX TPG RE Finance Trust Inc.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.